Skip to Content

David F. Sorensen

Managing Shareholder
P: 215.875.5705
F: 215.875.4604
dsorensen@bm.net Download vCard

David F. Sorensen is a managing shareholder and co-chair of Berger & Montague's antitrust department.  He graduated from Duke University (A.B. 1983) and Yale Law School (J.D. 1989), and clerked for the Hon. Norma L. Shapiro (E.D. Pa.).  He concentrates his practice on antitrust and environmental class actions.

Mr. Sorensen was on the trial team that won the "Trial Lawyer of the Year" award in 2009 from the Public Justice Foundation for its work on Cook v. Rockwell Int'l Corporation, No. 90-181 (D. Colo.), which resulted in a jury verdict of $554 million in February 2006, after a four-month trial, on behalf of thousands of property owners near the former Rocky Flats nuclear weapons plant located outside Denver, Colorado.  The jury verdict is the largest in Colorado history, and is the first time a jury has awarded damages to property owners living near one of the nation's nuclear weapons sites.  In 2008, after extensive post-trial motions, the District Court entered a $926 million judgment for the plaintiffs.  The jury verdict in the case was vacated on appeal in 2010.  In 2015, on a second trip to the Tenth Circuit Court of Appeals, Plaintiffs secured a victory with the case being sent back to the district court.  In May 2016, the parties announced they had reached a proposed $375 million settlement.  He has been designated a "Super Lawyer" by Philadelphia Magazine many years in a row.

Mr. Sorensen played a major role in the firm's representation of the State of Connecticut in State of Connecticut v. Philip Morris, Inc., et al., in which Connecticut recovered approximately $3.6 billion (excluding interest) from certain manufacturers of tobacco products.

Mr. Sorensen also has played a leading role in numerous antitrust cases representing direct purchasers of prescription drugs.  These cases have alleged that pharmaceutical manufacturers have wrongfully kept less expensive generic drugs off the market, in violation of the antitrust laws.  Many of these cases have resulted in substantial cash settlements, including King Drug Co. v. Cephalon, Inc., (E.D. Pa.) ($512 million partial settlement - largest ever for a case alleging delayed generic competition); In re Prandin Direct Purchaser Antitrust Litigation ($19 million settlement); In re Doryx Antitrust Litigation ($15 million); In re Skelaxin Antitrust Litigation ($73 million); In re Wellbutrin XL Antitrust Litigation ($37.50 million); In re Oxycontin Antitrust Litigation ($16 million); In re DDAVP Direct Purchaser Antitrust Litigation ($20.25 million); In re Nifedipine Antitrust Litigation ($35 million); In re Terazosin Hydrochloride Antitrust Litigation, MDL 1317 (S.D. Fla.) ($74.5 million); and In re Remeron Antitrust Litigation ($75 million).  He is serving as co-lead class counsel or on the executive committee of numerous similar, pending cases.

Prominent Judgments & Settlements